FDA’s pathway for novel pharmaceutical manufacturing has bifurcated. The Advanced Manufacturing Technologies (AMT) designation program, published in final form in the Federal Register on January 2, 2025, now sits alongside the older Emerging Technology Program (ETP) that CDER’s Office of Pharmaceutical Quality stood up in 2014. ETP keeps its early-stage engagement role; AMT designation is the formal status sponsors can request once a method is mature enough to point at a specific product.

What FDA wrote

The final AMT guidance defines an AMT as “innovative approaches in pharmaceutical manufacturing that are intended to improve the reliability and robustness of production processes.” It names continuous manufacturing, real-time process monitoring (Process Analytical Technology, PAT), 3D printing, and automated inspection as examples. The program covers drugs regulated by CDER or CBER and accepts requests from applicants, contract manufacturers, and technology developers.

The final version drops a passage from the 2023 draft that would have made an Emerging Technology Team (ETT) or CBER Advanced Technologies Team (CATT) meeting a near-prerequisite. Question 7 of the FAQ instead positions ETT and CATT as the venue for earlier-stage discussions, with AMT designation aimed at “methods and technologies that, while still novel (or used in a novel way), are more mature, such as those for which model drug-specific data to support eligibility are available.”

Two further deliverables sit in the PDUFA VII commitments. FDA is to issue an ETT activities report and update the ETP guidance, originally published in 2017, by the end of 2026.

What it changes for operators

For sponsors deploying continuous manufacturing or inline process analytical technology, the practical effect is a clearer ladder: ETT meetings first when the technology is still being characterised, then AMT designation when a specific product application is in sight. The benefits of designation are concentrated on the interaction side (early advice, a named AMT lead, written responses) rather than expedited review. The 2017 ETP guidance refresh, due this year, is the next near-term document to watch, particularly for vendors and CMOs whose first FDA contact is through ETT rather than through a sponsor’s application.